

Abstract

Provided by the present invention is a PD-1 binding molecule, which contains an anti-PD-1 single-domain antibody. The complementarity-determining region (CDR) of the single-domain antibody comprises CDR1 shown in SEQ ID NO:1, CDR2 shown in SEQ ID NO:2, and CDR3 shown in SEQ ID NO:3.